Sermorelin Side Effects: Safety Profile, Risks & What to Expect (2026)
From Peptidepedia, the trusted peptide wiki.
Medical Advisory Board
Side Effects
Sermorelin has a well-established safety profile from its years as an FDA-approved medication. The following adverse effects have been reported in clinical trials and post-marketing experience:
Common (typically mild and self-limiting):
Injection site reactions: pain, redness, swelling, or itching at the injection site, the most frequently reported adverse event in clinical studies
Facial flushing: a brief warm, red sensation in the face and neck, typically resolving within 5 to 20 minutes post-injection
Headache: mild headache reported in a subset of patients, most commonly during the first 1 to 2 weeks of therapy
Dizziness or lightheadedness, particularly with initial doses
Less common:
Nausea
Drowsiness or restlessness
Transient urticaria (hives)
Mild water retention
Difficulty swallowing (reported rarely with the injectable form)
Altered taste perception
Rare but clinically significant:
Hypersensitivity reactions: severe allergic symptoms including facial swelling, difficulty breathing, or anaphylaxis. These require immediate medical attention
Antibody formation: a large proportion of pediatric patients in clinical trials developed anti-sermorelin antibodies at least once during treatment, though antibody presence at one assessment often became negative by the next and did not appear to affect growth outcomes in most cases
Precautions and contraindications:
Active malignancy (GH and IGF-1 may promote growth of existing tumors)
Hypothyroidism should be corrected before initiating therapy, as low thyroid function impairs GH response
Concomitant glucocorticoid therapy may attenuate sermorelin's effects
Obese patients may have blunted GH responses to sermorelin
Frequently Asked Questions
The most frequently reported side effects are mild injection site reactions (redness, swelling, itching), transient facial flushing lasting a few minutes, and headache, particularly during the first 1 to 2 weeks of therapy. Most side effects resolve as the body adjusts to treatment.
In the United States, sermorelin can be legally obtained with a prescription from a licensed compounding pharmacy. The FDA confirmed in 2013 that Geref was not withdrawn for safety or efficacy reasons, which allows it to be compounded under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.
References
Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308.
Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96.
Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37.
Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159.
FDA. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register. 2013;78(42):14219-14220.
World Anti-Doping Agency. The 2025 Prohibited List International Standard.
Sermorelin Acetate. RxList Drug Database.
PubChem. Sermorelin (CID 16132413).
Sermorelin. DrugBank (DB00010).